Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7180576

COC(C)Oc1ccc(PC(=O)c2c(C)cccc2Cl)c(C)c1.[Li]

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 1/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ ABL1 P00519 1/20 0.32
▸ SRC P12931 1/20 0.32
▸ ITGB1 P05556 4/20 0.32
▸ ITGA4 P13612 4/20 0.32
▸ ITGB7 P26010 2/20 0.32
▸ ITGA2 P17301 1/20 0.32
▸ FABP3 P05413 1/20 0.32
▸ FABP4 P15090 1/20 0.32
▸ TRPM4 Q8TD43 1/20 0.31
▸ MCL1 Q07820 1/20 0.31
▸ PIK3CD O00329 1/20 0.31
▸ ALDH2 P05091 1/20 0.31
▸ CCR8 P51685 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7186703 0.96 TDP1 (0.35) KMT2ATP53MAPTMEN1PKM
Lithium SCHEMBL7188424 0.92 TDP1 (0.36) KMT2AMEN1TDP1
Lithium SCHEMBL7190318 0.91 MAPT (0.35) KMT2AMAPTMEN1TDP1ITGB1
Lithium SCHEMBL7180495 0.89 MEN1 (0.35) TYK2KMT2ATP53MAPTMEN1
SCHEMBL7179731 0.89 ABL1 (0.33) TYK2KMT2ATP53MAPTMEN1
SCHEMBL7177496 0.88 TYK2 (0.37) TYK2KMT2ATP53MAPTMEN1
SCHEMBL7174928 0.85 MAPT (0.39) TYK2KMT2AMAPTMEN1ABL1
Lithium SCHEMBL7180248 0.85 MEN1 (0.37) KMT2ATP53MAPTMEN1PKM
SCHEMBL7187626 0.84 SMN1; SMN2 (0.34) TYK2KMT2ATP53MAPTMEN1
SCHEMBL7187692 0.84 ALDH1A1 (0.38) TYK2KMT2ATP53MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TYK2 1285/4885KMT2A 1586/4885TP53 3575/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TYK2 1333/4885KMT2A 956/4885TP53 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.